How the World’s Most Expensive Drug War Became the Most Expensive

The World Health Organization’s (WHO) annual report for 2017 is the latest salvo in its battle against the drug industry.

The World Trade Organization (WTO) had approved more than 1.5 million pharmaceuticals, the most since the 1970s, and the UN’s World Health Assembly (WHOHAS) had unanimously approved 1.3 million, the highest number since 1992.

This is despite the fact that the WHO’s report, released last week, revealed a record number of deaths and serious medical conditions due to prescription opioids worldwide.

The WHO’s most recent data, from 2017, also found that nearly 4 million people died of prescription drug overdoses in the United States alone.

However, it is the pharmaceutical industry’s lobbying prowess that is driving the push for more drug war policies, particularly in Europe.

The pharmaceutical industry, which is pushing for the U.S. to lift its ban on exports of its opioids, is hoping to pressure the European Union (EU) to allow imports of its painkillers.

The EU, which has an estimated $20 trillion in annual sales, has long been a leading advocate of the drug war, and now it has a new ally in its fight against the opioid crisis.

The drug industry has lobbied hard for the passage of the opioid legislation in the European Parliament, which passed the bill in June.

The lobbying group for the pharmaceuticals industry, the European Commission, has been actively lobbying European countries to allow their citizens to obtain drugs from the United Kingdom.

It has also pushed for increased access to prescription drugs in the U